ASPCF News and Press, Acerus Pharmaceuticals Corp From 08/23/22

Acerus Pharmaceuticals ( OTCQB:ASPCF ) CFO Robert Motz  to resign from the company effective November 20, 2022. The company has begun a process to search for a new CFO and will provide an update at a future date. “I would like to thank Bob f...

TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his decision to resign as Chief Financial Officer effective N...

Acerus Pharmaceuticals Corporation (ASPCF) Q2 2022 Earnings Conference Call August 9, 2022 10:00 ET Company Participants Edward Gudaitis - President & Chief Executive Officer Robert Motz - Chief Financial Officer Conference Call Participants Present...

Acerus Pharmaceuticals press release ( OTCQB:ASPCF ): Q2 GAAP EPS of -$1.03. Revenue of $0.76M (+49.0% Y/Y). Gross profit for the second quarter of 2022 was $0.3 million compared to $0.5 million in the prior-year period. Cash as of June 30, 2022 was $1.3 million compar...

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and six-month period ended June 30, 2022. Unless otherwise noted, all amounts are...

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Genera...

TORONTO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2022 financial and operating results on Tuesday, August 9, 2022 before the market opens. The company will also host a conference call on Tuesday, August 9, 2...

TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on June 27, 2022. The total number of shares represented in person or by prox...

Acerus Pharmaceuticals (OTCQB:ASPCF) amends agreement with First Generation Capital, to increase its existing secured loan facility from $35.845 million to $37.945 million. This increase was made available to the company by way of a single advance of $2.1 million on June 23, 2022 under a secu...

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) ...